Analyse génétique comparée de 19 formes recombinantes VIH-1 inter-groupes M et O et impact évolutif

International audienc

Epidémie d'hépatite A aiguë parmi des hommes ayant des rapports sexuels avec des hommes (HSH) Caractéristiques cliniques et épidémiologiques des cas diagnostiqués au CHU de Rouen

International audienc

HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors

International audienceObjectivesTo determine natural phenotypic susceptibility of non-group M HIV-1 to integrase strand transfer inhibitors (INSTIs) in a large panel of 39 clinical strains from groups O, N and P and to identify genotypic polymorphisms according to susceptibility levels.MethodsSusceptibility to raltegravir, elvitegravir and dolutegravir was evaluated in 36 HIV-1/O, 2 HIV-1/N and 1 HIV-1/P strains plus an HIV-1/M reference strain. IC50 values were determined after 3 days, and fold changes (FCs) were calculated relative to the HIV-1/M strain. Genotypic polymorphism was determined by amplification of codons 19–263 of the integrase; the natural occurrence of resistance-associated mutations was analysed using the main resistance algorithms and the IAS-USA list. VESPA analysis of the strain sequences was used to determine a signature pattern associated with higher FC.ResultsSimilar IC50 results were observed for the three drugs. Based on the value for the HIV-1/M reference strain, the data showed FC values  10 for six strains (15%). Analysis of the non-M integrase sequences showed a high level of polymorphism without a major genotypic impact; it also revealed mutations that may be associated with the highest FC values obtained for elvitegravir.ConclusionsOur phenotypic data showed that non-M strains are globally susceptible to the three currently used INSTIs, but the impact of the high FC values observed for some strains with elvitegravir needs to be explored. Clinical data are now needed to confirm these phenotypic results

Analyse génétique comparée de 19 formes recombinantes VIH-1 inter-groupes M et O et impact évolutif

International audienc

ANRS 12168 - Dynam-O study, comparing the immuno-virological and clinical responses to HAART between HIV-1 group O and group M-infected patients : results at 96 weeks

International audienc

Epidémie d'hépatite A aiguë parmi des hommes ayant des rapports sexuels avec des hommes (HSH) Caractéristiques cliniques et épidémiologiques des cas diagnostiqués au CHU de Rouen

International audienc

Comparative immunovirological and clinical responses to antiretroviral therapy between HIV-1 Group O and HIV-1 Group M infected patients

Background. Little is known about impact of genetic divergence of human immunodeficiency virus type 1 group O (HIV-1/O) relative to HIV-1 group M (HIV-1/M) on therapeutic outcomes. We aimed to determine if responses to standardized combination antiretroviral therapy (cART) were similar between groups despite strain divergence. Methods. We performed an open nonrandomized study comparing the immunological, virological, and clinical responses to cART based on 2 nucleoside reverse transcriptase inhibitors plus 1 ritonavir-boosted protease inhibitor, in naive and paired HIV-1/O vs HIV-1/M infected (+) patients (ratio 1:2), matched on several criteria. The primary endpoint was the proportion of patients with undetectable plasma viral load (pVL, threshold 60 copies/mL) at week (W) 48. Secondary endpoints were the proportion of patients with undetectable pVL at W24 and W96 and CD4 evolution between baseline and W24, W48, and W96. Results. Forty-seven HIV-1/O+ and 94 HIV-1/M+ patients were included. Mean pVL at baseline was significantly lower by 1 log for HIV-1/O+ vs HIV-1/M+ patients. At W48, no significant difference was observed between populations with undetectable pVL and differences at W24 and W96 were not significant. A difference in CD4 gain was observed in favor of HIV-1/M at W48 and W96, but this was not significant when adjusted on both matched criteria and pVL at baseline. Conclusions. Our data demonstrate similar immunovirological and clinical response between HIV-1/O+ and HIV-1/M+ patients. They also reveal significantly lower baseline replication for HIV-1/O variants, suggesting specific virological properties and physiopathology that now need to be addressed

Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

International audienc

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

International audienc